Antiretroviral therapy (ART) became more widely available in the Russian Federation in 2006 when the Global Fund made a contribution to purchase ART with a mandate to increase numbers of patients receiving it. Funds were distributed to AIDS Centers and selected hospitals, and numbers quickly increased. Though ART is highly effective for adherent patients, dropout has been a problem; thus understanding characteristics of patients who remain on ART vs. those who leave treatment may provide information to facilitate engagement. We retrospectively assessed depression, hopelessness, substance use, viral load, and CD4+ counts of 120 patients who dropped out of ART for ≥12 months (Lost-to-Care, LTCs) and 120 who continued for ≥12 months (Engaged-in-Care, EICs). As expected, LTCs had higher viral loads and depression, lower CD4+ counts, more alcohol, heroin, and injection drug use in the past 30 days. A binary logistic regression with Center for Epidemiologic Studies Depression score, Beck Hopelessness score, whether drugs/alcohol had ever prevented them from taking ART, and past 30 days' alcohol use [ χ 2 (4) = 64.27, p = .0.000] correctly classified 74.5% of participants as LTC or EIC, suggesting that integrated treatment for substance use, psychiatric, and HIV could reduce dropout and improve outcomes.
Introduction
Of 1.5 million HIV+ Eastern Europeans and Central Asians, over two-thirds are in the Russian Federation (RF; UNAIDS, 2010). In St. Petersburg, rising heroin addiction in the 1990s led to increased HIV among injecting drug users (IDUs; Krupitsky et al., 2004; Krupitsky, Zvartau, Lioznov, et al., 2006) , followed by sexual transmission (Pokrovsky & Ladnaya, 2010) . Antiretroviral therapy (ART) was unavailable except for pharmaceutical trials involving patients with no addictions history/low relapse risk. The RF developed testing and counseling programs at hospitals and IDU clinics and established AIDS Centers for testing, counseling, and registration for ART were it to become available. In 2006, the Global Fund money was distributed, and requirements of no addiction history or extended remission were relaxed. ART patients increased from a handful in [2005] [2006] to 125,623/720,014 registered cases in the RF and 8571/42,639 in St. Petersburg by late 2012 (Lioznov, 2013, personal communication, August 25) . Treatment is available only at specialized hospitals or regional centers for CD4+ count <350 and/or viral load >100,000 and/or opportunistic infection, or maternal transmission prevention (Lioznov, Ruutel, Uuskula, & DeHovitz, 2011; Ministry of Health and Social Development 2006) .
Though patients are informed of adherence's importance, dropout is problematic; understanding patients who remain (Engaged-in-Care; EICs) vs. those who leave (Lost-to-Care; LTCs) may guide interventions. Depression and substance use have been shown to negatively impact engagement and adherence in other cultures (e.g., inner-city US, Pecoraro et al., 2013) , but few studies have examined attrition in the RF. In a prior St. Petersburg study (Pecoraro et al., 2014) , EIC and LTC focus groups identified structural barriers: stigma/discrimination; problems with providers and access; and individual barriers: employment/caring for dependents; inaccurate beliefs about ART (only LTCs); side effects; substance use (LTCs, present; EICs, past) ; and depression. In the present study, we compared demographics, depression, hopelessness, drug/alcohol use, trust, and biomarkers on those who dropped out of ART for ≥12 months (LTCs; n = 120) with those who continued for ≥12 months (EICs; n = 120) in St. Petersburg/Leningrad Oblast.
Methods

Design
Participants were from Leningrad Regional AIDS Center (LRAC), Botkin Hospital for Infectious Diseases (BHID), and St. Petersburg AIDS Center. The University of Pennsylvania's and Pavlov State Medical University's IRBs granted approval.
Participant selection and recruitment
Clinic physicians identified potential participants, aged ≥18, and capable of informed consent. LTCs had begun ART but not attended clinic in the past 12 months or been treated elsewhere and were contacted by phone. EICs kept ≥90% of appointments and had good adherence according to records and Adherence Index scores >10 (Mannheimer et al., 2006) . Random selection was not used due to recruitment difficulties. Participants received 1000 rubles (~US $32) for effort.
Data collection and analysis
Participants completed self-reports: demographics, social support, health, adherence, beliefs about HIV, reasons for retention/attrition, and substance use; Center for Epidemiologic Studies Depression Scale (CES-D; Radloff, 1977) ; Beck Hopelessness Scale (BHS; Beck, Kovacs, & Weissman, 1975) ; Risk Assessment Battery (RAB; Metzger, Nalvaline, & Woody, 2001) ; SF-36 (Ware, Gandek, & the IQOLA Project Group, 1994) ; Trust in Physician Scale (TIPS; Anderson & Dedrick, 1990) . Approved Russian translations of the CES-D, SF-36, and RAB were used. Two Russian physicians translated the BHS and TIPS and checked the translations for consensus. EICs' CD4+ count and viral load (VL) were obtained from clinic records, and LTCs brought their most recent results from general hospitals or addictions systems. 1 All results were dated within 90 days of study intake. Assessments took 45 minutes.
Results
Demographics
Participants were white (99%), male (60%), and heterosexual (96%). More EICs were employed part or full time (>30 hours/week) [64% vs. 39%; χ 2 (1, N = 240) = 15.02, p = .000]. A majority of all (72%), but more LTCs [78% vs. 68%; χ 2 (1, N = 240) = 4.02, p = .05], reported infection through needle sharing. Similar proportions (33% vs. 35%) reported sexual transmission (Table 1) . EICs' average CASE Adherence Index Score was 14.06 (SD = 1.95).
LTCs' reasons for attrition
Drug and/or alcohol use (63%); depression (38%); anxiety (41%); the belief that ART was not helping (28%) or was not important to health (29%); not knowing that stopping ART is harmful (41%); poor social/familial support (26%); side effects (42%) were common reasons for attrition. Of the 71% who wanted to return to treatment, it was because they did not feel well (46%); or had stopped/reduced drug (38%) or alcohol use (36%).
Social support
LTCs and EICs expressed satisfaction with personal relationships (7.13 vs. 6.74 on a 10-point scale), but EICs perceived more support [2.39 (SD = 0.87) vs. 1.77 (SD = 1.04); t(237) = 5.45, p = .000] and rated friends/family as helping more to remember medications [1.77 (SD = 1.04) vs. 1.48 (SD = 1.08); t(237) = 2.18, p = .030].
Biomarkers and health
VLs and CD4+ counts (CD4+) were available for 80% of LTCs and 55% of EICs. EICs had higher CD4+ counts [420.48 (SD = 189.56) vs. 234.70 (SD = 158.98); p = .000] and lower viral loads [log 10 = 4.22 (4.81) vs. log 10 = 5.39 (5.72); p = .001] (Table 2) . However, even among EICs, the VL was much higher than typical for fully adherent patients. According to the WHO, >5000 copies are considered virological failure (WHO, 2010), and <1000 copies indicate suppression in low-and middle-income countries (Bennett, Bertagnolio, Sutherland, & Gilks, 2008) . The RF is a developing, uppermiddle-income country (World Bank, 2014) . Of the 66 EICs on whom VLs were available, 53 (80%) had a viral load <200, and one was undetectable; of 96 LTCs, 17 (18%) had a VL <200, and none were undetectable.
On ratings of current health from 0 to 100 (worst possible-perfect), EICs rated themselves better (67.4) vs. (51.4) [t(238) = 6.04, p = .000]. On the SF-36 (Ware et al., 1994) , EICs rated every aspect of health better (Table 3) .
Drugs, alcohol and mental health status
Significantly more LTCs used alcohol, benzodiazepines, or heroin in the past 30 days, but oral opiate, amphetamine, and marijuana use were similar. More LTCs reported drinking several times per week or daily [27% vs. 8%; χ 2 (1, N = 240) = 15.56, p = .000] or injecting drugs [25% vs. 10%; χ 2 (1, N = 240) = 9.35, p = .002] in the past 30 days (Table 4 ). More LTCs [64% vs. 28%; χ 2 (1, N = 240) = 30.99, p = .000] reported that drug/ alcohol use had ever prevented them from taking ART.
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EICs' average CES-D score, 13.74, was just under the threshold (15) for minor depressive symptoms, but LTCs average score of 21.13 was in the major depression range (p < .000). LTCs expressed more hopelessness on the BHS (p < .000), but both groups were in the "mild" range (Table 5 ).
Risk behaviors
LTCs had higher levels of drug (p = .012) and sex (p = .049) risk behaviors on the RAB (Metzger et al., 2001) (Table 6) .
Punishment beliefs and stigma
Participants indicated agreement with statements on HIV as punishment and stigma (Mimiaga et al., 2010 ) from 1-strongly disagree to 7-strongly agree). LTCs agreed more with two of the three statements on punishment and the statement on shame/stigma (p = .015-.005) (Table 7) .
Trust in physician scale
EICs had higher trust according to the Trust in Physician Scale (TIPS) [40.08 (SD = 7.47) vs. 36.22 (SD = 8.67); t(235) = 3.67, p = .000].
Logistic regression
A logistic regression was performed on LTC/EIC status as the dependent variable and the following predictors, without covariates: CES-D, BHS, whether drugs or alcohol had ever prevented them from taking ART (binary), and drinking in the past 30 days (binary). Analysis was performed using SPSS 19.
A test of the full model against a constant-only model was significant, χ 2 (4) = 64.27, p = .000. The predictors reliably distinguished LTCs from EICs, with 76.5% of EICs and 72.3% of LTCs correct, for an overall 74.5% success rate. Table 8 shows regression coefficients, Wald statistics, odds ratios, and 95% confidence intervals for Alcohol use 38 (32%) 58 (62%) χ 2 (1, N = 240) = 9.87, p = .002* Alcohol a few times per week or every day 9 (8%) 32 (27%) χ 2 (1, N = 240) = 15.56, p = .000* Heroin 10 (8%) 26 (22%) χ 2 (1, N = 240) = 8.37, p = .004* Benzodiazepines 4 (3%) 12 (10%) χ 2 (1, N = 240) = 4.29, p = .04* Oral opiate painkillers 30 (25%) 24 (20%) χ 2 (1, N = 240) = 0.93, NS Amphetamines 4 (3%) 10 (8%) χ 2 (1, N = 240) = 2.73, NS Marijuana 15 (13%) 15 (13%) χ 2 (1, N = 240) = 2.73, NS Any injection drug use 12 (10%) 30 (25%) χ 2 (1, N = 240) = 9.35, p = .002* *Statistically significant; NS, not significant. AIDS Care 89 odds ratios for each predictor. According to the Wald criterion, all variables were reliable predictors. The odds ratios for drugs or alcohol ever having prevented them from taking ART and having drunk alcohol in the past 30 days were moderate but weak for the other predictors.
Discussion and conclusions
Among this group of patients in the Russian Federation, substance use (particularly alcohol and heroin) and depression were more prevalent among LTCs. The high substance use among all participantsand the disproportionate number of LTCs infected through needle sharingdemonstrates IDU's role in the epidemic (e.g., Lioznov et al., 2011) . Of great concern is the high VL, even among EICs, since it facilitates transmission and increases chances of treatment failure (Novitsky & Essex, 2012) . Finding that 71% of LTCs wanted to return to treatment is promising, but institutional barriers (i.e., long waiting lists) as well as personal barriers should be addressed. Results are commensurate with prior research (Pecoraro et al., 2014) and provide evidence of substance use and depression as factors associated with LTCs. Limitations include retrospectiveness and non-random selection, which prevent the conclusion that the identified factors cause attrition. However, they are associated with it, and findings should be taken seriously. Future research might involve a prospective study in which substance use and depression are measured at clinic intake, and attrition is tracked. Interventions to prevent attrition should be tested: depression and substance use screening upon clinic intake and co-located psychiatric and substance abuse treatment. Possible interventions could include: Cognitive-Behavioral Therapy for depression and inaccurate beliefs about ART, Motivational Interviewing to address ambivalence (Miller & Rollnick, 2012) , adherence interventions such as 230 Life Steps (Safren, Otto, & Worth, 1999; Safren et al., 2001) , and extended-release naltrexone 2 (e.g., Krupitsky, Zvartau, Masalov, et al., 2006; Krupitsky et al., 2011 Krupitsky et al., , 2012 with psychosocial support to prevent relapse. 
